This study is for kids and young adults with solid tumors that came back after treatment or never fully went away. It tests two medicine combinations to find the highest safe doses. One group (Arm A) gets Onivyde and talazoparib, and the other (Arm B) gets Onivyde and temozolomide. Onivyde damages the cancer cell's DNA, and talazoparib or temozolomide stops the cell from fixing the damage, which may kill the cancer cells. The goal is to see if these medicines help the tumors go away.
- The study lasts up to 24 months with medicine given on specific days and regular check-ups.
- Participants will be randomly placed in one of two groups to receive different medicine combinations.
- There is a focus on safety and determining the best doses of the medications.
The study includes children and young people aged 12 months to 30 years old. Participants must have a specific type of tumor that cannot be cured otherwise. Regular check-ups will help monitor any side effects or changes in the tumor. This study could help find new ways to treat these tough cancers.